secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-031670
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx reports Q3 net loss of $2.1M; cash at $8.1M; Phase III interim analysis expected Q4 2022
--------------------------------------------------------------------------------

- Net loss of $2.1 million for Q3 2022, up from $1.5 million in Q3 2021.
- Cash and short-term marketable securities of $8.1 million as of Sep 30, 2022; 9.07M shares outstanding.
- G&A expenses rose to $1.3M from $0.6M, driven by post-IPO support and D&O insurance premiums.
- Expects first prospective interim analysis of Phase III TIGeR-PaC trial in pancreatic cancer in Q4 2022.
- Plans to launch Phase II/III trial in extrahepatic cholangiocarcinoma in Q4 2022/Q1 2023; appointed Angela Gill Nelms as COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/0001493152-22-031670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer